DEFENCE THERAPEUTICS A - DTCFF STOCK NEWS

Defence Therapeutics Inc. announces successful testing of second-generation anti-cancer vaccine ARM-002TM with promising results in melanoma model. The vaccine shows an 80% complete response rate when combined with anti-PD-1 immune-checkpoint inhibitor. Defence reprogrammed MSCs using AccuTOX® to create a potent antigen presenting cell vaccine, reducing antigen preparation challenges. The company plans to expand testing to ovarian and pancreatic cancers and initiate Phase I trials targeting solid tumors.

Defence Therapeutics Inc. announces the closing of the 2nd tranche of its non-brokered private placement, raising $600,000 for advancing preclinical and clinical programs.

Defence Therapeutics Inc. receives US patent for its breakthrough AccuTOX technology, providing market exclusivity until 2042. The technology induces cancer cell death and shows promising results in pre-clinical studies, leading to FDA approval for Phase I clinical trials in melanoma patients.

Defence Therapeutics Inc. announces a peer-reviewed study on its Accum®-E7 vaccine for cervical cancer treatment. The study, published in Cancer Science, highlights the vaccine's dual anti-cancer properties, prophylactic and therapeutic benefits, and safety profile. Defence also updates on a private placement offering.

Defence Therapeutics Inc. announces the closing of the 1st tranche of its non-brokered private placement, raising $850,500.00. The Company intends to use the net proceeds to advance its preclinical and clinical programs, including the Phase I clinical trial of Defence's AccuTOX administered intratumorally in patients with stage IIIB to IV melanoma, and for general working capital. The Offering consists of units priced at $1.50 per Unit, each containing one common share and one common share purchase warrant. The Company paid a cash finder's fee of $68,040.00 and issued Finder's Warrants to a certain qualified arm's length finder. All securities issued in connection with the Offering are subject to a statutory hold period of four months plus a day from their date of issue in accordance with applicable securities legislation.

Defence Therapeutics Inc. announces an amendment to its financing, conducting a non-brokered private placement of up to $2,250,000. The company will use the net proceeds to advance its preclinical and clinical programs, including the Phase I clinical trial of Defence's AccuTOX administered intratumorally in patients with stage IIIB to IV melanoma, and for general working capital.

Defence Therapeutics Inc. announces a non-brokered private placement of up to $2,790,000 to advance its preclinical and clinical programs, including the Phase I clinical trial of Defence's AccuTOX®. The company's common shares have been upgraded to OTCQB, and are now trading under the symbol 'DTCFF'.

Defence Therapeutics Inc. (DTC) successfully tested a new formulation of its ACCUM-002TM Dimer CDCA-SV40, known as AccuTOX®, for lung-established tumors. The drug demonstrated enhanced therapeutic properties and broader application in cancer therapeutics, with successful preclinical studies and FDA clearance to begin a Phase I trial in patients with melanoma. The global cancer therapeutics market size is expected to reach US$393.61 billion by 2032, presenting significant growth opportunities for the company.

Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) announces FDA approval for Phase I clinical trial of AccuTOX™, a first-in-class injectable anticancer molecule for solid cancer tumors.